ICTI Announces Promotions
Interactive Clinical Technologies Incorporated, (ICTI) is pleased to announce two recent promotions.
April 28, 2005, Yardley, PA - Interactive Clinical Technologies Incorporated, (ICTI) is pleased to announce two recent promotions.
Valarie L. Higgins has been appointed Vice President, Clinical Services. Since joining ICTI six years ago, she has served in increasingly important positions in clinical operations management. Her contributions have been instrumental in establishing ICTI's reputation for high-quality customer service. Most recently Ms Higgins was Director, Clinical Services at ICTI. Earlier in her career, she was a Research Assistant for Covance. Ms. Higgins holds a BA in Psychology from Rutgers University.
Marsha B. Rehrer has been promoted to Director, Software Testing Services, from Associate Director. Throughout her career, Ms. Rehrer has held positions of expanding responsibility in software development, quality assurance and operations. Her recent promotion recognizes the value she has brought and will continue to bring to ICTI's growing product base. Ms. Rehrer holds a BS in English from Davis & Elkins College in Elkins, WV.
Richard McCann, President of ICTI, noted. "To continue to provide our clients unparalleled service and software, we need highly qualified, talented individuals at all levels of our company. I am pleased that Val and Marsha will have increased influence on our quality and service."
About ICTI and Almac Sciences
ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; phone-based patient diaries; iTrial EDC for clinical trials data; and forecasting for clinical trials supplies planning.
Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDX (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
